CDK4 and gastric cancer: To evaluate the sensitivity of GC toward CDK4/6 inhibition, we performed the drug-dose response assays among a panel of 13 human GC cell lines treated with abemaciclib (abbreviated to ABE hereafter) (Fig. 1E).